This last week the orthopedic market did not roar. It sorted.
Stryker agreed to buy Zurich’s ZuriMED and its FiberLocker needle—an answer to rotator-cuff patches that cheese-wire through bad tendon. Enovis put €155 million on Grenoble’s eCential Robotics, hoping that stack becomes a knee robot by late 2028. Nanochon put a 3D-printed cartilage scaffold into a human knee in Panama. A California planner launched a data lake meant to sit on top of everybody else’s implants. A public SI micro-cap took a $3 million dilution round; a founder-funded spine shop hired a closer instead of raising; a German limb-salvage frame found a U.S. distributor in time for AOFAS. The pattern is blunt: strategics will pay for fixation, an engineering bench, or minutes off an ASC room. They will not pay for another elegant implant, floor tower, or camera that still cannot answer who writes the check.
Let's jump into the details.
M&A: Stryker Acquires Swiss Soft-Tissue Specialist ZuriMED
The Deal: Stryker entered into a definitive agreement to acquire Zurich-based ZuriMED Technologies AG. Terms remain undisclosed. This marks Stryker’s second notable 2026 purchase following Amplitude Vascular Systems.
T...
